SOPHiA GENETICS (SOPH) Competitors $3.26 +0.16 (+5.16%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends SOPH vs. ETNB, PLRX, RLAY, KROS, AVXL, IMNM, KURA, TYRA, ERAS, and CRONShould you be buying SOPHiA GENETICS stock or one of its competitors? The main competitors of SOPHiA GENETICS include 89bio (ETNB), Pliant Therapeutics (PLRX), Relay Therapeutics (RLAY), Keros Therapeutics (KROS), Anavex Life Sciences (AVXL), Immunome (IMNM), Kura Oncology (KURA), Tyra Biosciences (TYRA), Erasca (ERAS), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. SOPHiA GENETICS vs. 89bio Pliant Therapeutics Relay Therapeutics Keros Therapeutics Anavex Life Sciences Immunome Kura Oncology Tyra Biosciences Erasca Cronos Group SOPHiA GENETICS (NASDAQ:SOPH) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, community ranking, analyst recommendations and risk. Does the MarketBeat Community favor SOPH or ETNB? 89bio received 89 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. However, 73.08% of users gave SOPHiA GENETICS an outperform vote while only 64.67% of users gave 89bio an outperform vote. CompanyUnderperformOutperformSOPHiA GENETICSOutperform Votes1973.08% Underperform Votes726.92% 89bioOutperform Votes10864.67% Underperform Votes5935.33% Does the media favor SOPH or ETNB? In the previous week, 89bio had 1 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 6 mentions for 89bio and 5 mentions for SOPHiA GENETICS. 89bio's average media sentiment score of 0.57 beat SOPHiA GENETICS's score of 0.32 indicating that 89bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SOPHiA GENETICS 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 89bio 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Is SOPH or ETNB more profitable? 89bio has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -110.71%. SOPHiA GENETICS's return on equity of -55.06% beat 89bio's return on equity.Company Net Margins Return on Equity Return on Assets SOPHiA GENETICS-110.71% -55.06% -38.33% 89bio N/A -59.58%-52.21% Which has stronger earnings and valuation, SOPH or ETNB? SOPHiA GENETICS has higher revenue and earnings than 89bio. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSOPHiA GENETICS$64.49M3.30-$78.98M-$1.09-2.9989bioN/AN/A-$142.19M-$2.91-2.73 Do insiders & institutionals believe in SOPH or ETNB? 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Comparatively, 2.8% of 89bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate SOPH or ETNB? SOPHiA GENETICS presently has a consensus target price of $7.40, suggesting a potential upside of 126.99%. 89bio has a consensus target price of $30.33, suggesting a potential upside of 282.03%. Given 89bio's stronger consensus rating and higher possible upside, analysts clearly believe 89bio is more favorable than SOPHiA GENETICS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SOPHiA GENETICS 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.8089bio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has more volatility and risk, SOPH or ETNB? SOPHiA GENETICS has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, 89bio has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Summary89bio beats SOPHiA GENETICS on 9 of the 17 factors compared between the two stocks. Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Get SOPHiA GENETICS News Delivered to You Automatically Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SOPH vs. The Competition Export to ExcelMetricSOPHiA GENETICSBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$213.12M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-2.9946.7391.3417.19Price / Sales3.30411.851,117.70116.80Price / CashN/A182.1042.6437.86Price / Book1.033.894.794.78Net Income-$78.98M-$42.21M$120.07M$225.60M7 Day Performance-0.61%-2.14%-1.90%-1.23%1 Month Performance4.15%4.21%11.45%3.37%1 Year Performance-25.91%18.40%30.63%16.58% SOPHiA GENETICS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SOPHSOPHiA GENETICS2.4453 of 5 stars$3.26+5.2%$7.40+127.0%-25.9%$213.12M$64.49M-2.99520Analyst ForecastNews CoveragePositive NewsETNB89bio1.78 of 5 stars$7.90+2.7%$30.33+284.0%-22.4%$838.40MN/A-2.6440News CoveragePositive NewsPLRXPliant Therapeutics3.3626 of 5 stars$13.72+3.2%$40.50+195.2%-19.0%$834.86M$1.58M0.0090RLAYRelay Therapeutics2.2511 of 5 stars$4.84+2.8%$20.50+323.6%-60.4%$810.12M$25.55M-1.80304Insider TradeKROSKeros Therapeutics3.2934 of 5 stars$19.42+3.1%$81.33+318.8%-49.6%$786.65M$651,000.00-3.61100High Trading VolumeAVXLAnavex Life Sciences3.3395 of 5 stars$9.18+8.5%$43.00+368.4%-2.5%$778.46MN/A-18.5440IMNMImmunome2.561 of 5 stars$12.44-1.1%$28.83+131.8%+33.0%$776.47M$10.13M-1.5540Positive NewsKURAKura Oncology4.48 of 5 stars$9.98+3.6%$29.38+194.3%-27.0%$776.05MN/A-4.08142TYRATyra Biosciences2.0666 of 5 stars$15.06+0.8%$31.00+105.8%+2.0%$762.04MN/A-9.2820ERASErasca2.0792 of 5 stars$2.62+2.3%$5.90+125.2%+35.8%$740.75MN/A-3.08126News CoveragePositive NewsGap UpCRONCronos Group1.8498 of 5 stars$1.93flat$3.00+55.4%+4.8%$737.84M$87.24M-15.19356News Coverage Related Companies and Tools Related Companies ETNB Alternatives PLRX Alternatives RLAY Alternatives KROS Alternatives AVXL Alternatives IMNM Alternatives KURA Alternatives TYRA Alternatives ERAS Alternatives CRON Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SOPH) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SOPHiA GENETICS SA Please log in to your account or sign up in order to add this asset to your watchlist. Share SOPHiA GENETICS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
